NovaBridge Biosciences (NBP) Cash & Equivalents (2018 - 2026)
NovaBridge Biosciences (NBP) recorded Cash & Equivalents of $190.64 million in Q2 2026, up 15.3% from $165.4 million a year earlier.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Cash & Equivalents (2018 - 2026) Analysis & Trends
At the end of FY2025, NovaBridge Biosciences reported Cash & Equivalents of $210.63 million, up 208.6% from FY2024.
- Annual Cash & Equivalents has a five-year compound annual growth rate of -22.0% (FY2020 to FY2025).
- Across earlier years, Cash & Equivalents came in at $68.26 million in FY2024 (-76.6%), $291.51 million in FY2023 (-15.0%), $342.92 million in FY2022 (-38.0%) and $552.94 million in FY2021 (-24.2%).
- Quarterly Cash & Equivalents has ranged from $53.6 million in Q1 2025 to $554.02 million in Q2 2022 over the past five years.
- On a year-over-year basis, Cash & Equivalents rose in four of the last five quarters, with growth averaging 68.6%.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 208.6% in Q4 2025, against a decline of 77.0% in Q4 2024 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | NovaBridge Biosciences | 149.78 Mn | 149.78 Mn | - | 190.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 190.64 Mn |
| Dec 31, 2025 | 210.63 Mn |
| Sep 30, 2025 | 228.06 Mn |
| Jun 30, 2025 | 165.40 Mn |
| Mar 31, 2025 | 53.60 Mn |
| Dec 31, 2024 | 68.26 Mn |
| Sep 30, 2024 | 79.33 Mn |
| Jun 30, 2024 | 151.96 Mn |
| Dec 31, 2023 | 297.42 Mn |
| Jun 30, 2023 | 325.40 Mn |
| Dec 31, 2022 | 451.90 Mn |
| Jun 30, 2022 | 554.02 Mn |
| Dec 31, 2021 | 551.13 Mn |
| Jun 30, 2021 | 672.48 Mn |
| Dec 31, 2020 | 718.07 Mn |
| Sep 30, 2020 | 435.96 Mn |
| Jun 30, 2020 | 220.81 Mn |
| Dec 31, 2019 | 161.39 Mn |
| Sep 30, 2019 | 239.82 Mn |
| Dec 31, 2018 | 229.71 Mn |
API Access
NovaBridge Biosciences Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=NBP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "NBP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=NBP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();